<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04921995</url>
  </required_header>
  <id_info>
    <org_study_id>2021052-1</org_study_id>
    <nct_id>NCT04921995</nct_id>
  </id_info>
  <brief_title>Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <acronym>RETICULA-NPC</acronym>
  <official_title>Postponing or Omitting Re-irradiation After Tislelizumab Plus Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single center, phase II trial to evaluate the safety and efficacy of&#xD;
      postponing or omitting re-irradiation after first-line systemic therapy with tislelizumab and&#xD;
      chemotherapy in patients with unresectable recurrent loco-regionally advanced nasopharyngeal&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reirradiation is usually recommended for unresectable recurrent loco-regionally advanced&#xD;
      nasopharyngeal carcinoma. However, it potentially adds to the RT-related severe toxicities&#xD;
      and deaths. This trial aims to investigate the feasibility of postponing or even omitting&#xD;
      re-irradiation based on effective first-line systemic therapy with tislelizumab and&#xD;
      chemotherapy. In this single arm trial, all patients will receive chemotherapy (on doctors'&#xD;
      recommendation) and PD-1 antibody (tislelizumab 240mg every three weeks). Patients with no&#xD;
      response to the systemic therapy will receive salvage radiotherapy, while those who showed&#xD;
      complete or partial response will continue maintenance therapy until progression, death or&#xD;
      intolerable toxicity, and reirradiation will be postponed or omitted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Defined as either a confirmed CR or a PR, as determined by the investigator using RECIST v1.1Response Evaluation Criteria in Solid Tumors (RECIST) .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress-free survival (PFS)</measure>
    <time_frame>2 year</time_frame>
    <description>Defined from date of randomization to date of first documentation of progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 year</time_frame>
    <description>Defined from date of randomization to date of first documentation of death from Defined from date of randomization to date of first documentation of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>2 year</time_frame>
    <description>Analysis of adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>1 year</time_frame>
    <description>QoL scores were assessed by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTCQLQ-C30).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <condition>Unresectable Nasopharyngeal Carcinoma</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Immunotherapy</condition>
  <condition>Intensity-modulated Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given tislelizumab plus investigator's choice chemotherapy, with re-irradiation postponed or omitted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Chemotherapy (including but not limited to following):&#xD;
GP regimen: gemcitabine 1000mg/m2 d1, d8 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4 cycles; TP regimen: docetaxel 75mg/m2 d1 + cisplatin 25 mg/m2 d1-3, every 3 weeks for 4 cycles; GT regimen: gemcitabine 1000mg/m2 d1 + docetaxel 75mg/m2 d1, every 2 weeks for 6 cycles; S-1 : twice per day oral dose of 40mg for BSA&lt;1.25, 50 mg for 1.25≤BSA&lt;1.5 and 60mg for BSA≥1.5.&#xD;
anti-PD-1 antibody: Tislelizumab concurrently with chemotherapy: 200mg, every 3 weeks for 12 weeks. Tislelizumab in maintenance period: 200mg every 3 weeks or 400mg every 6 weeks, until one year or disease progression, or in the case of intolerable toxicities.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as local recurrence ± regional recurrence after ≥1 year of radical&#xD;
             treatment;&#xD;
&#xD;
          2. Not suitable for surgery;&#xD;
&#xD;
          3. Clinical stage rT3-4N0-2 (rII-IVa, AJCC/UICC 8th);&#xD;
&#xD;
          4. ECOG score 0-1;&#xD;
&#xD;
          5. No prior treatment to rNPC, such as radiotherapy, chemotherapy, immunotherapy or&#xD;
             biotherapy;&#xD;
&#xD;
          6. No contraindications to immunotherapy or chemoradiotherapy;&#xD;
&#xD;
          7. Adequate marrow function: WBC count ≥ 3×10E9/L, NE count ≥ 1.5×10E9/L, HGB ≥ 90g/L,&#xD;
             PLT count ≥ 100×10E9/L;&#xD;
&#xD;
          8. Adequate liver function: ALT/AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;&#xD;
&#xD;
          9. Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥&#xD;
             60ml/min (Cockcroft-Gault formula);&#xD;
&#xD;
         10. Take effective contraceptions during and two months after treatment;&#xD;
&#xD;
         11. Patients must be informed of the investigational nature of this study and give written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have local necrosis in recurrent lesions, estimated with bleeding risk;&#xD;
&#xD;
          2. Unexplained fever &gt; 38.5 ℃, except for tumor fever;&#xD;
&#xD;
          3. Treated with ≥ 5 days antibiotics one month before enrollment;&#xD;
&#xD;
          4. Have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis,&#xD;
             nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy);&#xD;
&#xD;
          5. Have a known history of human immunodeficiency virus (HIV), active Hepatitis B&#xD;
             (HBV-DNA ≥10E3copiers/ml) or hepatitis C virus (HCV) antibody positive;&#xD;
&#xD;
          6. Have ≥G3 late toxicities, except for skin, subcutaneous tissue or mucosa;&#xD;
&#xD;
          7. Have previously treated with PD-1 antibody or other immunotherapy for PD-1/PD-L1&#xD;
             pathway;&#xD;
&#xD;
          8. Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial&#xD;
             -infarction within 1 year, or clinically meaningful arrhythmia that requires&#xD;
             treatment;&#xD;
&#xD;
          9. Have known allergy to large molecule protein products or any compound of study&#xD;
             therapy;&#xD;
&#xD;
         10. Pregnant or breastfeeding;&#xD;
&#xD;
         11. Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical&#xD;
             cancer, and papillary thyroid carcinoma;&#xD;
&#xD;
         12. Any other condition, including mental illness or domestic/social factors, deemed by&#xD;
             the investigator to be likely to interfere with a patient's ability to sign informed&#xD;
             consent, cooperate and participate in the study, or interferes with the interpretation&#xD;
             of the results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoshen Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye and ENT Hospital of Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoshen Wang, MD.</last_name>
    <phone>0086-021-64377134</phone>
    <email>ruijin702@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eye and ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoshen Wang, MD.</last_name>
      <email>ruijin702@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.fdeent.org/Major</url>
    <description>Eye and ENT Hospital of Fudan University homepage</description>
  </link>
  <reference>
    <citation>Kong F, Zhou J, Du C, He X, Kong L, Hu C, Ying H. Long-term survival and late complications of intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. BMC Cancer. 2018 Nov 20;18(1):1139. doi: 10.1186/s12885-018-5055-5.</citation>
    <PMID>30453915</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, Peng J, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23. Erratum in: Lancet. 2016 Oct 15;388(10054):1882.</citation>
    <PMID>27567279</PMID>
  </reference>
  <reference>
    <citation>Liu LT, Chen QY, Tang LQ, Zhang L, Guo SS, Guo L, Mo HY, Zhao C, Guo X, Chen MY, Qian CN, Zeng MS, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ. With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case-control study. BMC Cancer. 2016 Oct 7;16(1):774.</citation>
    <PMID>27717335</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaoshen Wang</investigator_full_name>
    <investigator_title>Director of Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

